| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1365-2796.1990.TB00157.X |
| P698 | PubMed publication ID | 2182759 |
| P2093 | author name string | K Landin | |
| L Tengborn | |||
| U Smith | |||
| P433 | issue | 4 | |
| P921 | main subject | hypertension | Q95566669 |
| plasminogen | Q107129060 | ||
| cardiovascular disease | Q389735 | ||
| P304 | page(s) | 273-278 | |
| P577 | publication date | 1990-04-01 | |
| P1433 | published in | Journal of Internal Medicine | Q6295387 |
| P1476 | title | Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease | |
| P478 | volume | 227 |
| Q40621879 | Antihypertensive drugs: issues beyond blood pressure control |
| Q36947544 | Association between the rs6950982 polymorphism near the SERPINE1 gene and blood pressure and lipid parameters in a high-cardiovascular-risk population: interaction with Mediterranean diet |
| Q42034651 | Biocompatibility of cerium dioxide and silicon dioxide nanoparticles with endothelial cells |
| Q48788406 | Cerebrovascular disorders caused by hyperfibrinogenaemia |
| Q36812008 | Circadian variation in fibrinolytic activity in patients with variant angina |
| Q33704612 | Clinical implications of elevated PAI-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: a case report and review of the literature |
| Q40421375 | Clinical implications of insulin resistance syndromes |
| Q24796861 | Close relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas |
| Q51579418 | Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance. |
| Q36344440 | Effects of Aerobic Fitness and Adiposity on Coagulation Biomarkers in Men vs. Women with Elevated Blood Pressure |
| Q42321345 | Effects of Epinephrine on Inflammation-Related Gene Expressions in Cultured Rat Cardiomyocytes |
| Q41500157 | Effects of calcium antagonists on insulin sensitivity and other metabolic parameters |
| Q58823401 | Effects of isradipine sustained release on platelet function and fibrinolysis in essential hypertensives with or without other risk factors |
| Q82052278 | Efficacy of olmesartan therapy on fibrinolytic capacity in patients with hypertension |
| Q86450783 | Elevated plasminogen activator inhibitor type-1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome |
| Q80505490 | Endothelial dysfunction in diabetes mellitus |
| Q71819548 | Enhanced Levels of Tissue-Type Plasminogen Activator in Borderline Hypertension |
| Q40566627 | Exercise and diet in the prevention and control of the metabolic syndrome |
| Q24336335 | Fibrinogen-induced endothelin-1 production from endothelial cells |
| Q35667573 | Fibrinogen-induced increased pial venular permeability in mice |
| Q74137868 | Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol |
| Q33542798 | Growth hormone deficiency and cardiovascular risk |
| Q45884243 | Haemostasis balance disorders in patients with essential hypertension |
| Q41675668 | Hemostatic concomitants of syndrome X |
| Q64946763 | Hyperfibrinogenemia-mediated astrocyte activation. |
| Q51573704 | Hyperinsulinemia and hypofibrinolysis: effects of short-term optimized glycemic control with continuous insulin infusion in type II diabetic patients. |
| Q54081357 | Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. |
| Q43572315 | Hypertension and non-insulin dependent diabetes |
| Q37786770 | Hypertriglyceridaemia, triglyceride-rich lipoproteins and coronary heart disease |
| Q77463126 | Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals |
| Q73484494 | Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden |
| Q37374639 | Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis |
| Q34110733 | Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles |
| Q40812885 | Insulin resistance and risk factors for coronary heart disease |
| Q82266687 | Insulin resistance explains the relationship between novel cardiovascular risk factors and hypertension. The Telde Study |
| Q40560110 | Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease |
| Q45287104 | Insulin resistance, hyperinsulinemia, and cardiovascular disease. The need for novel dietary prevention strategies |
| Q36319877 | Knockout of SOD1 alters murine hepatic glycolysis, gluconeogenesis, and lipogenesis |
| Q73096122 | Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjects |
| Q37590371 | Mechanisms of fibrinogen-induced microvascular dysfunction during cardiovascular disease |
| Q40948177 | Metabolic abnormalities in cardiac ischemia. |
| Q34031701 | Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training |
| Q33796880 | Metabolic syndrome: is equine disease comparable to what we know in humans? |
| Q39652813 | New atherosclerosis risk factors in obese, hypertensive and diabetic children and adolescents |
| Q51580851 | No influence of proinsulin and insulin on plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator in young women before and during intake of contraceptive steroids. |
| Q44510088 | PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population |
| Q79329776 | Parental history of hypertension is associated with coagulation-fibrinolytic balance disorders |
| Q34310277 | Pathophysiology of oxidative stress in diabetes mellitus |
| Q42844910 | Plasma Plasminogen Activator Inhibitor 1 (PAI-1) and p-Selectin Levels in Urgent Hypertension: Effect of Single Dose Captopril and Nifedipin on Fibrinolytic Activity |
| Q80347661 | Plasma levels of fibrinogen and C-reactive protein are related to interleukin-6 gene -572C>G polymorphism in subjects with and without hypertension |
| Q33832519 | Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity |
| Q45926880 | Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina |
| Q51266144 | Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus. |
| Q34384926 | Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease |
| Q34376916 | Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. |
| Q73589915 | Plasminogen activator inhibitor-1, the acute phase response and vitamin C |
| Q71845877 | Platelet function and fibrinolytic activity during rest and exercise in borderline hypertensive patients |
| Q54176580 | Reduction of free fatty acids may ameliorate risk factors associated with abdominal obesity |
| Q73995202 | Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy |
| Q74099004 | Relation of serum triglyceride levels to survival after coronary artery bypass grafting |
| Q74182587 | Relationship between lipoprotein(a) phenotypes and plaminogen activator inhibitor type 1 in diabetic patients |
| Q51599356 | Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. |
| Q51579395 | Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians. |
| Q42489280 | Relationships between fibrinogen and insulin resistance |
| Q46103338 | Role of diet and exercise in the management of hyperinsulinemia and associated atherosclerotic risk factors |
| Q33613823 | Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease |
| Q47289966 | Systolic and diastolic blood pressure related to six other risk parameters in Turkish adults: strong correlation with relative weight |
| Q83306169 | The effect of high plasma levels of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor (PAI-1) on the reperfusion after thrombolytic therapy in patients presented with acute myocardial infarction |
| Q42465243 | The effect of number of days in culture and plasminogen activator inhibitor-1 (PAI-1) 4G/5G genotype on PAI-1 antigen release by cultured human umbilical vein endothelial cells |
| Q40927887 | The effects of metformin on cardiovascular risk factors |
| Q37119116 | The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients |
| Q40582016 | The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey |
| Q41171807 | Therapeutic challenges in the obese diabetic patient with hypertension |
| Q71177644 | Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion--the 'PKC syndrome' |
| Q71618741 | Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension |
Search more.